Kasey(Henderson)LegerMD
Pediatric Hematology & Oncology • Seattle, WAAssociate Professor, Pediatrics, University of Washington School of Medicine; Medical Director of the Leukemia and Lymphoma Program, Seattle Children's Hospital; Affiliate Member, Fred Hutchinson Cancer Research Center
Dr. Leger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4800 Sand Point Way NE
Stop MB8
Seattle, WA 98105Phone+1 206-987-5509Fax+1 206-987-3964
Summary
- Dr. Kasey (Henderson) Leger is a Pediatric Hematology and Oncology specialist based in Seattle, WA. She completed her pediatrics residency at the University of Colorado and a fellowship in Pediatric Hematology/Oncology at the University of Texas Southwestern Medical Center. Dr. Leger has served as an attending physician at Seattle Children's Hospital since 2014. She is the Medical Director of Seattle Children's Leukemia & Lymphoma Program and an Associate Professor of Pediatrics at the University of Washington School of Medicine. Her published research includes studies on pediatric hematological malignancies and therapy related cardiotoxicities, with recent work featured in journals such as the JACC Cardio Oncology, Journal of American Society of Echocardiography, and JAMA Network Open. Additionally, she is involved in clinical trials investigating cardioprotection during cancer treatment.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2010 - 2013
University of ColoradoResidency, Pediatrics, 2006 - 2009
McGovern Medical School at UTHealthClass of 2006
Certifications & Licensure
WA State Medical License 2014 - 2025
TX State Medical License 2013 - 2014
CO State Medical License 2009 - 2011- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Start of enrollment: 2014 Mar 05
Publications & Presentations
PubMed
- -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.Sara K Silbert, Samantha Scanlon, Hao-Wei Wang, Constance M Yuan, Alyssa Doverte
Journal for Immunotherapy of Cancer. 2024-10-26 - 1 citationsBuilding a machine learning-assisted echocardiography prediction tool for children at risk for cancer therapy-related cardiomyopathy.Lindsay A Edwards, Christina Yang, Surbhi Sharma, Zih-Hua Chen, Lahari Gorantla
Cardio-Oncology. 2024-10-09 - 1 citationsUtility of apical four-chamber longitudinal strain in the assessment of childhood cancer survivors: A multicenter study.Matthew J Mosgrove, Ritu Sachdeva, Kayla L Stratton, Saro H Armenian, Aarti Bhat
Echocardiography. 2024-02-01
Grant Support
- Cardiac studies in Children's Oncology Group study AAML1831: A Phase 3 randomized trial for children with de novo AML comparing standard induction with dexrazoxane to CPX-351Jazz Pharmaceuticals2020–2027
- Cardiotoxicity Prediction in Children with Acute Myeloid Leukemia (AML)National Cancer Institute Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)2020–2026
- Scholar in Clinical Research Career Development ProgramLeukemia & Lymphoma Society2019–2024
Committees
- Founding member, current chair, International Cardio Oncology Society, Pediatric Working Group 2021 - Present
- Chair, Children's Oncology Group Myeloid Committee, Cardiotoxicity Working Group 2016 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
